Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities of patients along their healthcare journey, but which data type is most useful and when? With HealthVerity and Symphony Health now coming together,...
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues its...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic restructuring...
Open claims vs. closed payer claims: What’s the difference?
Open claims and closed payer claims data are essential for understanding the status and activities...
MASH disease: From silent epidemic to treatment options
Liver disease is a growing global health concern, yet many of its most serious forms remain...
Why reliable mortality measurement in real-world evidence matters
Understanding mortality in taXonomy and the importance of post mortem activity This is the third...
Why underpowered studies are more dangerous than you think
In epidemiology, statistical power determines whether a study can accurately detect an effect of a...
When billed and allowed amounts aren’t enough: HealthVerity market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our...
Does your data link?
How clinical data linkage closes evidence gaps in real-world data Clinical data linkage helps...
Why 'good enough' data is risky
Real World Data (RWD) is increasingly being incorporated into healthcare and life science research...